CHICAGO, Nov 29 (Reuters) — The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives.
Drugmakers Eisai Co Ltd (4523.T) and Biogen (BIIB.O)
Reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo [ read more.
Comments are closed.